This site is intended for UK healthcare professionals

 

Menarini BEACON series

This interactive BEACON session explores the management of younger patients at high lifetime cardiovascular risk whose QRISK® scores may underestimate their true risk. The faculty will examine how to identify patients who would benefit from earlier intervention, interpret lifetime versus 10-year cardiovascular risk, and optimise lipid-lowering and cardiovascular risk reduction strategies in line with current evidence and guidelines.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

This interactive BEACON session explores the optimisation of secondary cardiovascular prevention in patients with established atherosclerotic cardiovascular disease. Herein, the faculty will examine how to identify and address residual cardiovascular risk, optimise lipid-lowering therapy beyond statins, and implement evidence-based strategies to achieve recommended LDL-C targets.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

In this interactive BEACON session, the faculty explore the management of cardiovascular risk in people with type 2 diabetes. They examine how to optimise lipid-lowering therapy, blood pressure control and glucose management, alongside addressing renal risk and implementing evidence-based interventions to reduce long-term cardiovascular complications.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

In this interactive BEACON session, the faculty explore the complexities of managing multifactorial cardiometabolic risk in primary care, looking at the fictional case of a 67-year-old man with long-standing type 2 diabetes, CKD stage 3a with rising albuminuria, obesity and multiple modifiable risk factors.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.